$APRI trading stopped then resumed down 67% close
Post# of 97987
down 67% closed $1.04
2/1/6/18
FDA cannot approve the NDA for Vitaros
in its present form, identifying deficiencies related to Chemistry,
Manufacturing and Control ("CMC" and certain safety concerns specific
to the 2.5% concentration of DDAIP.HCl contained in the current
formulation.